\
&
Contact us
\
&
Contact us
The aim of the European Commission is to increase the competitiveness of the different European transport industries and achieve a European transport system that is resource-efficient, climate-and environmentally-friendly, safe and seamless for the benefit of all citizens, the economy and society. This is translated into these 4 objectives:
1) To make sure the industry shows more respect for the environment by making vehicles, aircrafts, vessels, etc. more ecologic and resource-efficient
2) To create better mobility, less congestion, more safety and security with a substantial reduction of traffic congestion
3) To ensure that the European transport industry becomes a global leader
4) To stimulate the socio-economic and behavioral research and forward looking activities for policy making. This way they want to make sure the societal challenges brought upon by the increase of transport are better addressed.
The work program is based on these four objectives and consists of these categories for Calls for proposals:
- Mobility for growth
- Green vehicles
- Small business and Fast Track innovation for transport
- Other actions to complement the first three categories
info@ncpflanders.be
+32 2 550 15 65
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
